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ABSTRACT 
 
Background & Aims: Crohn’s disease (CD) usually recurs after intestinal resection; post-
operative endoscopic monitoring and tailored treatment can reduce chance of recurrence. 
We investigated whether monitoring levels of fecal calprotectin (FC) can substitute for 
endoscopic analysis of the mucosa. 
 
Methods: We analyzed data collected from 135 participants in a prospective, randomized, 
controlled trial, performed at 17 hospitals in Australia and 1 in New Zealand, that assessed 
the ability of endoscopic evaluations and step-up treatment to prevent CD recurrence after 
surgery. Levels of FC, serum levels of c-reactive protein (CRP), and Crohn’s disease 
activity index (CDAI) scores were measured before surgery and then 6, 12, and 18 months 
after resection of all macroscopic Crohn’s disease. Ileo-colonoscopies were performed at 6 
months after surgery in 90 patients and 18 months after surgery in all patients. 
 
Results: Levels of FC were measured in 319 samples from 135 patients. The median FC 
decreased from 1347 µg/g before surgery to 166 µg/g at 6 months after surgery, but was 
higher in patients with disease recurrence (based on endoscopic analysis; Rutgeerts score 
≥i2) than patients in remission (275 µg/g vs 72 µg/g; P<.001). Combined 6- and 18-month 
levels of FC correlated with the presence (r=0.42; P<.001) and severity (r=0.44; P<.001) of 
CD recurrence, but level of CRP and CDAI score did not. Levels of FC >100 µg/g indicated 
endoscopic recurrence with 89% sensitivity and 58% specificity, and a negative predictive 
value (NPV) of 91%; this means that colonoscopy could have been avoided for 47% of 
patients. Six months after surgery, levels of FC<51 µg/g in patients in endoscopic remission 
predicted maintenance of remission (NPV, 79%). In patients with endoscopic recurrence at 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 months who stepped-up treatment, levels of FC decreased from 324 µg/g at 6 months to 
180 µg/g at 12 months and 109 µg/g at 18 months. 
 
Conclusion: In an analysis of data from a prospective clinical trial, measurement of FC has 
sufficient sensitivity and NPV values to monitor for CD recurrence after intestinal resection. 
Its predictive value might be used to identify patients most likely to relapse. After treatment 
for recurrence, FC level can be used to monitor response to treatment. It predicts which 
patients will have disease recurrence with greater accuracy than level of CRP or CDAI 
score. 
 
KEYWORDS: Inflammatory Bowel Disease; Fecal Biomarkers; Prognostic Factor; 
Prognosis 
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INTRODUCTION 
 
Approximately seventy percent of patients with Crohn’s disease will require intestinal 
resection at some time in their life and, of these, up to 70 percent require a second 
operation.1 Endoscopically-identified post-operative disease recurrence occurs early and its 
severity predicts the subsequent clinical course. Within weeks of resection, new aphthous 
ulceration in the neo-terminal ileum can be identified,2 with disease recurrence identifiable 
endoscopically in 70 percent of patients at one year.3  
 
Monitoring of Crohn’s disease activity is often based on a combination of clinical 
assessment and biological markers of inflammation. However, there is often insufficient 
correlation between the clinical state and biological markers to engender confidence in their 
use as the sole basis for monitoring or treatment decision-making.4, 5 Endoscopy is the gold 
standard for detecting and quantifying bowel inflammation, but is expensive, labor intensive, 
inconvenient for the patient and carries some risk.6 The correlation between clinical scoring 
systems, such as the Crohn’s Disease Activity Index (CDAI) and the Harvey Bradshaw 
Index (HBI), and endoscopic findings in Crohn’s disease is poor.7, 8 The correlation between 
serum biochemical markers of inflammation, such as C-reactive protein (CRP), and 
endoscopic findings in Crohn’s disease is also inconsistent.7, 9  
 
We have recently undertaken a controlled clinical trial examining different strategies for 
managing patients after Crohn’s disease resection of all macroscopic disease.10 The Post-
Operative Crohn’s Endoscopic Recurrence (POCER) study has demonstrated that initial 
post-operative therapy according to clinical risk of recurrence, with colonoscopy performed 
six months after intestinal resection and treatment step-up for recurrence, is significantly 
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superior to standard drug therapy alone, in preventing post-operative Crohn’s disease 
recurrence. This study utilized ileo-colonoscopy as the main means for disease monitoring. 
However the limitations of colonoscopy create a need for a non-invasive measure to identify 
disease recurrence after surgery.11 As yet no simple diagnostic test has been validated 
against endoscopy in large populations to monitor for disease recurrence post-operatively.  
 
Calprotectin is a member of the S100 family of calcium-binding proteins12 and is abundant 
in all body fluids in proportion to the degree of inflammation present.13 It can be readily 
quantified in feces using enzyme-linked immunosorbent assay (ELISA) or an immunoassay. 
 
Fecal calpotectin (FC) has been shown to reflect endoscopic disease activity in Crohn’s 
disease.8, 9 FC is more sensitive than CDAI or CRP at detecting endoscopic inflammation,9, 
14
 and is a reliable surrogate marker of mucosal healing in patients with Crohn’s disease.8, 
15
 Increased FC concentrations are associated with an increased risk of clinical relapse.16-21 
Its value in the post-operative setting, however, is uncertain.      
 
Only small studies have evaluated the role of fecal biomarkers post-operatively, few have 
correlated measurements with endoscopic findings, and results have been inconsistent.22-27 
FC concentrations have been shown to fall after intestinal resection for Crohn’s disease.25 
Lobaton et al studied 29 patients post-operatively, and demonstrated that the FC 
concentration was significantly lower among those in remission (i0 and i1) than those with 
recurrent disease (98 vs. 235µg/g, p=0.012).26 Lasson and colleagues22 studied 30 patients 
for one year post-operatively performing monthly FC and ileo-colonoscopy at one year. One 
year after surgery the median values of FC were not significantly different between the 
patients in endoscopic remission (n=17) and the patients with an endoscopic recurrence 
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(n=13) 189 vs. 227µg/g; p=0.25. However, most patients with low values were in remission 
and all patients with high (>600µg/g) FC values had recurrent disease.   
 
These data suggest an emerging role for FC in monitoring patients in the post-operative 
setting. However prospective, longitudinal evaluation of fecal biomarkers in a large post-
operative population with colonoscopy performed early is required to fully determine the 
role of this test in this setting. Whether FC can replace colonoscopy in monitoring for 
Crohn’s disease recurrence post-operatively needs to be determined.  
  
The aim of this study was to examine whether FC, CRP or CDAI can be used as surrogate 
markers of recurrent mucosal lesions in the neo-terminal ileum and at the anastomosis. 
This study aimed to determine the accuracy of these biomarkers in reflecting the presence 
and severity of recurrent disease, and predicting future recurrence, following intestinal 
resection of all macroscopic disease.   
 
MATERIALS AND METHODS 
 
The Clinical Post-Operative Recurrence Study 
 
The POCER study was a prospective, randomized, controlled trial which aimed to assess 
the value of post-operative endoscopic assessment and treatment step-up for early 
mucosal recurrence.10 Patients were stratified according to risk of recurrence. Smokers, 
patients with perforating disease, or patients with ≥1 previous resections were classified as 
“high-risk”; all others were “low-risk”. All patients underwent resection of all macroscopic 
disease.  
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Patients may have had previous upper gut disease (Table 1), but to be included in the study 
no residual upper gut disease was present at the time of surgery. Patients were permitted 
to be on proton pump inhibitor therapy for symptomatic reflux disease. Patients were not 
permitted to be on aspirin or NSAID therapy and were instructed to avoid these during the 
study.    
 
Immediately post-operatively all patients received 3 months of metronidazole. High-risk 
patients also received daily azathioprine (2mg/kg/day) or 6-mercaptopurine (1.5mg/kg/day). 
High risk patients intolerant of thiopurine received adalimumab induction (160mg/80mg) 
and then 40mg two-weekly. Low-risk patients received no further medication.  
 
Patients were randomized to colonoscopy at 6 months (active care) or no colonoscopy 
(standard care). For endoscopic recurrence (Rutgeerts score ≥i2) at 6 months patients 
stepped-up to thiopurine, fortnightly adalimumab with thiopurine, or weekly adalimumab. 
The primary end-point was endoscopic recurrence at 18 months. Endoscopic remission 
was defined as Rutgeert’s score i0 or i1 (i0 = no lesions, i1 = mild small superficial 
anastomotic lesions), and recurrence defined as i2, i3 or i4 (moderate to severe lesions).  
 
One hundred and seventy four patients were included at 17 hospitals in Australia and one 
in New Zealand.  One hundred and one of 122 patients randomized to endoscopic 
intervention (6 month colonoscopy) were high-risk, compared to 44 of 56 in the standard 
care arm (Figure 1). 
 
As part of the study protocol stool samples were taken pre-operatively (baseline), and at 6, 
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12 and 18 months post-operatively for calprotectin measurement. Also at these time points 
CDAI was calculated and serum CRP measured.  
 
All patients provided written informed consent before inclusion in the study. Ethical approval 
for the study was obtained from the Human Research Ethics Committees of the 
participating hospitals, and the trial registered (Clinical Trial Registration: NCT00989560). 
 
Endoscopic Visual Assessment 
 
At ileo-colonoscopy mucosal recurrence at the anastomosis and neo-terminal ileum was 
assessed according to the Rutgeerts score3 by the endoscopist, who was not blinded to 
patient treatment. Photographs of the anastomosis and neo-terminal ileum were, however, 
scored again by two senior investigators (PDC and MAK) blinded to the endoscopist’s score 
and the patient’s identity and treatment. A final consensus score was determined by the two 
blinded assessors.  
 
For the 6 and 18 month colonoscopies endoscopic remission was defined as Rutgeerts 
score i0 (no lesions) or i1 (≤5 aphthous lesions) and recurrence as i2 (>5 aphthous lesions 
or larger lesions confined to anastomosis), i3 (diffuse ileitis), or i4 (diffuse inflammation with 
large ulcers and/or narrowing)3. Two secondary measures of endoscopic disease activity 
were also calculated: the Crohn’s Disease Endoscopic Index of Severity (CDEIS)28 and the 
Simple Endoscopic Score for Crohn’s Disease (SES-CD),29 to  ensure robustness of the 
Rutgeerts score.  
 
Stool collection and storage 
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Stool samples were collected pre-operatively when a patient joined the study before 
surgery and collected at 6, 12 and 18 months after surgery. Patients were instructed to 
collect stool samples no more than three days prior to the study visit, or if colonoscopy was 
to be performed, three days prior to colonoscopy before commencing bowel preparation. 
Samples were stored at -20 degrees Celsius in patients’ home freezer, transported on ice, 
stored at -80 degrees Celsius at study centres until conclusion of the clinical study. All 
samples were then analyzed simultaneously in a central laboratory. 
 
Fecal Biomarker Assays 
 
FC was measured by a quantitative enzyme immunoassay (Smart-Prep, Bühlmann, 
Schonenbuch, Switzerland) as per manufacturer’s instructions, without knowledge of 
patient data. Concentrations were expressed as µg/g of stool.   
 
The upper limit of the normal range of FC in patients without gut inflammation is well 
defined as <50µg/g.30 
 
Statistical analysis 
 
For the clinical POCER study10 the sample size was based on an alpha value of 0·05 (1-
sided), 80% power, and expected endoscopic disease recurrence at 18 months for 
standard care of 60% and for active care of 35%, based on previous studies.31,32 Allowing 
for a 31% drop-out of patients 170 patients (113 active and 57 standard care arms) were 
needed.  The sample size for the study was based on the clinical study design comparing 
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two management strategies to prevent disease recurrence. It was not based on the 
calprotectin component of the study which was not separately powered. 
 
Data were analyzed using STATA12 (StataCort, Texas, USA). Associations between 
categorical data were assessed using either Chi-square or Fisher’s exact test. Associations 
between endoscopic disease and FC, CDAI, and CRP were assessed by logistic regression 
analysis for binary outcomes and by the determination of Spearman’s rank correlation 
coefficient (rho) for non-parametric correlations. The optimal cut-off values for FC 
concentration for assessment and prediction of endoscopic recurrence were determined 
using logistic regression in combination with the senspec command in STATA12 and 
Youden Index.33, 34   
 
There were three cohorts used for analysis:  
 
Cross Sectional Analysis 
 
This analysis allowed for median FC concentrations at all time-points (pre-operative, 6, 12 
and 18 months) to be calculated.    
 
Endoscopic Validation Analysis 
 
The patients included in this analysis are shown in Table 1. This analysis included FC 
measurements taken at 6 or 18 months in which an endoscopic assessment was performed 
at the same time point. FC, CRP and CDAI data from 6 and 18 month time-points were 
correlated to endoscopic recurrence (Rutgeerts scores i0 or i1) and scored endoscopic 
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severity (i0 - i4). 
 
To determine if FC can be used to predict future endoscopic recurrence FC from all patients 
in the standard care arm at six months (who did not undergo any treatment change 
between 6 and 18 months) were considered in relation to their endoscopic findings at 18 
months. FC results from patients in the active care arm in endoscopic remission at 6 
months (who also did not change treatment between 6 and 18 months) were considered in 
relation to their endoscopic findings at 18 months.  
 
Longitudinal Analysis 
 
Patients were included if they had provided ≥2 fecal samples during the period of post-
operative follow up, with at least one fecal sample matched to an endoscopic assessment 
performed at the same time point. This allowed determination of the relationship between 
FC, disease behavior, escalation of medical therapy and response to treatment step-up 
over time. 
 
RESULTS 
 
Figure 1 shows the study patient disposition. Demographic details of patients who provided 
stool samples are shown in Table 1.  
 
Baseline patient demographics were similar for the three analysis groups. The number of 
patients and samples that contributed to each analysis and the rates of endoscopic 
recurrence are detailed in Table 2. 
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Fecal Calprotectin Concentration in Relation to Surgery, Mucosal Recurrence and 
Remission 
 
Three hundred and nineteen fecal samples from 135 patients (44% male, median age 38 
years (range 28 - 40)) were studied (Table 1). At 6 months 91 patients underwent 
colonoscopy (active care arm) and of these 31 (32%) had endoscopic recurrence. At 18 
months 108 patients underwent colonoscopy, of whom 45 (33%) had endoscopic 
recurrence.  
 
FC concentrations were elevated pre-operatively (median 1402µg/g, IQR: 426µg/g-
2825µg/g). At 6 months FC concentration fell (all patients median 166µg/g, IQR: 56µg/g-
424µg/g), but was higher in those with recurrent endoscopic disease than endoscopic 
remission (275µg/g, IQR: 163µg/g-540µg/g vs. 72µg/g, IQR: 32µg/g-190µg/g, p<0.001) 
(Figure 2A). At 18 months FC concentration was higher in recurrent endoscopic disease 
than endoscopic remission (FC: 331µg/g, IQR: 159µg/g-550µg/g vs. 75µg/g, IQR: 37µg/g-
258µg/g, p<0.002) (Figure 2B). When 6 and 18 month observations were combined median 
FC in those with recurrent endoscopic disease was 330µg/g, IQR: 163 - 540 versus 75µg/g, 
IQR: 37 – 258, for those in endoscopic remission (p<0.001) (Figure 2C).  
 
 
The cut-off values for FC and corresponding sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV) and area under the receiver operator characteristic 
(AUROC) curve analysis results in detecting endoscopic recurrence are shown in Table 3. 
The calculated best cut-off for FC as a marker of endoscopic recurrence, from combined 6 
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and 18 month endoscopic observations, was 135µg/g. However for clinical utility and in 
order to optimize specificity, whilst maintaining optimal sensitivity and NPV, a best-fit cut-off 
of 100µg/g was selected. FC >100µg/g identified endoscopic recurrence (≥i2) with a 
sensitivity of 0.89, specificity of 0.58, PPV 53%, NPV 91%, and AUROC 0.763. AUROC for 
CRP and CDAI were significantly lower at 0.568 and 0.541 respectively when 6 and 18 
month observations were combined.     
 
Logistic regression showed that patients with FC >100µg/g at 18 months were significantly 
more likely to have endoscopic recurrence compared to those with FC ≤100µg/g (OR 10.5, 
95% CI 2.7-40.4, p=0.001).   
 
For the SES-CD a value of ≥4 is regarded as reflecting at least mildly active endoscopic 
Crohn’s disease.35 In the current study a FC of >139 was sensitive and modestly specific 
for a SES-CD ≥4 with a sensitivity of 0.79, specificity 0.63, PPV 56%, NPV 83% and 
AUROC 0.720. For the CDEIS a value of ≥6 reflects endoscopic Crohn’s disease activity, 
with an FC of >92 found to have a sensitivity of 0.73, specificity of 0.72, PPV of 90%, NPV 
44% and AUROC of 0.730.36  
 
Relationship Between Fecal Calprotectin Concentration and Endoscopic Findings 
 
One hundred and thirty six patients had matched endoscopic, FC, CRP and CDAI results 
available which were included in a correlation analysis. FC correlated with both the 
presence of endoscopic recurrence (r=0.42, p<0.001) and scored endoscopic severity 
(Rutgeert’s score) (r=0.44, p<0.001) when all 6 and 18 month endoscopic observations 
were considered. FC correlated with both the presence of endoscopic recurrence and 
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scored endoscopic severity when 6 (endoscopic recurrence r=0.49, p <0.001; endoscopic 
severity r=0.56, p<0.001) and 18 month (endoscopic recurrence r=0.38, p=0.002; 
endoscopic severity r=0.35, p = 0.004) outcomes were considered independently.  
 
CRP and CDAI did not correlate with FC, endoscopic recurrence or scored endoscopic 
severity. FC also correlated with SES-CD (r=0.49, p<0.001) and CDEIS (r=0.47, p<0.001). 
(Table 4).   
 
Nineteen patients had colonic recurrence, separate to the anastomosis, at 6 months, 18 
months or both. No patient with both colonic recurrence and anastomotic recurrence had a 
FC ≤100µg/g. Seven patients with colonic recurrence had no anastomotic recurrence; their 
FC ranged from 10-3040µg/g, with 5 patients >100µg/g. The two patients with colonic 
recurrence only and low FC had superficial colonic inflammation only. Twelve patients with 
colonic recurrence and anastomotic recurrence had a FC of 467- 4421µg/g.  
 
Extreme FC values were not completely reliable in excluding or confirming endoscopic 
recurrence. Five patients with FC ≤100µg/g had a Rutgeerts score indicating recurrence 
(Figure 2D). Of these five, two had a FC <50µg/g. Therefore even a low FC did not 
absolutely preclude disease recurrence, although it was unlikely.  Conversely a high 
concentration, for example FC >1000µg/g, was sometimes associated with no colonoscopic  
recurrence (data not shown), most likely due to either microscopic disease or upper gut 
disease. 
 
In our cohort, if colonoscopy was performed at 6 months post-operatively only in those with 
a FC >100µg/g, 47% of patients without endoscopic disease recurrence would have 
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avoided a colonoscopy. If colonoscopy was performed at 6 or 18 months post-operatively 
only in those with a FC >100µg/g colonoscopy would have been avoided in 58% of patients 
without endoscopic disease recurrence. Figure 2D shows all FC concentrations <300µg/g 
from the endoscopic validation cohort (combined 6 and 18 month observations). The dotted 
line illustrates the proposed cut-off of 100µg/g.  
 
When 6 and 18 month post-operative endoscopic assessments were considered five 
patients had endoscopic disease recurrence (four with i2 and one with i4) but a FC 
≤100µg/g (FC 20, 36, 50, 54 and 93 µg/g). Of these five patients, four had a paired CRP 
result available - only one (with i2 recurrence) had an elevated CRP (30mg/L).  
 
In patients who did not have an endoscopy at 6 months FC >100µg/g at 6 months predicted 
endoscopic recurrence (Rutgeerts ≥i2) at 18 months with a sensitivity 0.75, specificity 0.45, 
PPV 46%, NPV 74%, and AUROC 0.889. The optimal AUROC-derived cut-off in this group 
was determined as 252µg/g giving a sensitivity of 0.63, specificity 0.76, PPV 63%, and NPV 
76%.  
 
FC >100µg/g at 6 months in patients in endoscopic remission (i0 or i1) predicted 
subsequent recurrence at 18 months with a sensitivity 0.50, specificity 0.43, PPV 25%, NPV 
71%, and AUROC 0.477. The AUROC-derived optimal cut-off in this group was determined 
as 51µg/g giving a sensitivity 0.50, specificity 0.68, PPV 36% and NPV 79%.  
 
Fecal Calprotectin Concentration in Response to Treatment 
 
Fecal calprotectin decreased significantly in response to intensification of drug therapy 
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(Figure 3). In patients in the active study arm in endoscopic remission at 6 months who did 
not step-up medical therapy, median FC concentration rose from 129µg/g to 153µg/g at 12 
months (p=0.194) and 178µg/g at 18 months (p=0.245). In patients with endoscopic 
recurrence at 6 months who stepped-up treatment the median FC concentration at 6 
months fell from 324µg/g to 180µg/g at 12 months (p=0.005) and 109µg/g at 18 months 
(p=0.004).   
 
DISCUSSION 
 
The majority of patients with Crohn’s disease require a resection at some time, and most of 
these will come to a further operation. The POCER study has recently demonstrated that 
post-operative endoscopic monitoring, together with treatment intensification for early 
recurrence, is superior to standard drug therapy alone, in preventing disease recurrence, at 
least in the short term.10 However such endoscopic monitoring is invasive, expensive, 
cannot be repeated frequently, and, in some patients will yield a normal result. In two thirds 
of abdominal Crohn’s operations all macroscopically involved intestine is resected.37 Such a 
situation, of surgically-induced and verified remission, is an ideal starting-point for the use 
of a non-invasive marker to monitor for recurrent inflammation.  
 
In our study we have demonstrated that FC is markedly elevated prior to surgery and falls 
substantially after resection of all macroscopic disease at six months, consistent with 
findings from Lamb et al.25  
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The present study has demonstrated that FC is sufficiently sensitive to monitor recurrence 
of Crohn’s disease, and has a high enough negative predictive value to be confident that 
few patients with recurrence have been missed.  
 
The Rutgeerts endoscopic scoring system used in this study has not been formally 
validated. However the severity of the endoscopic findings one year post-operatively, based 
on this scoring system, has been shown previously to predict subsequent symptomatic 
recurrence.2 We used a Rutgeerts score of i2 to define recurrence, as in previous studies.  
This scoring system has also been used in other randomized, controlled trials of drug 
therapy in the post-operative setting, with good discrimination between treatment arms.32  
The outcomes observed using other endoscopic scoring systems provide support for the 
primary measure used in this study (Rutgeert’s score). Although the Crohn’s Disease 
Endoscopic Index of Severity (CDEIS)28 and the Simple Endoscopic Score for Crohn’s 
Disease (SES-CD)29 are not specific for the post-operative setting, they were used in the 
context of removal of all macroscopic disease.  
 
Selecting the most appropriate cut-off value for fecal calprotectin measurement is critical to 
its performance as a screening test. Such a value should have a high negative predictive 
value so that few patients with active disease are missed for subsequent colonoscopy. 
Whilst a cut-off of 50 µg/g has more commonly been used as a cut of to diagnose 
inflammatory bowel disease in patients presenting with gastrointestinal symptoms38 this 
value is inappropriate for evaluating patients with established Crohn’s disease. In patients 
with Crohn’s disease there is likely to be microscopic inflammation even in the setting of 
macroscopic normality which will marginally increase calprotectin but this is unlikely to be 
relevant clinically.  At each time point in our study a cut-off of 100µg/g had an NPV of ≥90% 
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with the best combination of sensitivity and specificity. Reducing the cut-off to 50µg/g in this 
study would have resulted in a marked reduction in test specificity to 0.38 with a reduction 
in PPV to < 50% rendering the test clinically irrelevant.  
 
A small number of patients had endoscopically detectable disease recurrence but had a 
normal fecal calprotectin concentration. CRP was not additionally helpful in identifying these 
patients.  
 
Fecal calprotectin measurement would appear to be of modest value in predicting future 
endoscopic recurrence in the post-operative setting.  A low fecal calprotectin in patients in 
endoscopic remission at six months had a limited predictive value for the development of 
endoscopic recurrence one year later. We therefore recommend serial measurement of 
fecal calprotectin at regular intervals in the post-operative period in preference to relying on 
a single FC measurement to predict future endoscopic behavior. It may be expected that 
repeated testing would improve test sensitivity. 
  
Our findings illustrate the potential value of fecal calprotectin testing routinely in the post-
operative setting as part of a management algorithm in asymptomatic patients. These 
results confirm the accuracy, utility and superiority of fecal calprotectin over CRP or CDAI 
as a monitoring tool and screening test for endoscopic recurrence of Crohn’s disease in the 
post-operative population. These data suggest that FC may have an important role in 
monitoring Crohn’s disease post-operatively, with colonoscopy reserved for those with an 
elevated calprotectin or those with a clinical indication.  
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It would appear that fecal calprotectin concentration measurement reflects the severity of 
endoscopic recurrence post-operatively (Table 4). Fecal calprotectin also appears to reflect 
the response to intensified drug therapy. Fecal calprotectin measurement may therefore 
have a further role in monitoring the response to treatment, with colonoscopy reserved for 
patients who fail to show a fall in calprotectin to within the normal range.  
      
In this study single calprotectin measurements were taken at specific time points. Although 
intra-individual variation may occur with repeat testing, it is most important whether there is 
substantial variation within the range of values that discriminates active from inactive 
disease. In this regard fecal calprotectin has been shown to have low day-to-day variability 
in Crohn’s disease patients.39, 40 Nonetheless every test needs to be considered in the 
clinical context, including the patient’s history, risk of recurrence, and the presence of 
symptoms.    
 
Our data suggest that fecal calprotectin can be used to monitor for recurrence and to follow 
patients’ response to treatment. These data do not suggest that such measurements 
replace the need for colonoscopy, but rather serve as a complementary investigation. 
Calprotectin could be measured frequently, to identify early and relatively-easily treated 
recurrence, with colonoscopy reserved for certain intervals. In patients who have had 
frequent or severe previous recurrences endoscopy may still be the preferred first-line 
investigation.   
 
To date small studies evaluating the utility of fecal calprotectin measurement to diagnosis 
post-operative recurrence have provided conflicting results.22-26 The strengths of this study 
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lie in the large sample size, prospective measurements, endoscopic validation, and 
longitudinal intra-individual assessment of fecal calprotectin.  
 
The small number of patients with severe recurrence (Rutgeerts score i3 - 5 patients and i4 
- 7 patients) limits conclusions regarding the role of fecal calprotectin in the diagnosis of 
severe post-operative recurrence.  
 
Interpretation of calprotectin measurement as a marker of anastomotic Crohn’s recurrence 
is limited by the possible effect of upper gastrointestinal ulceration or proximal small bowel 
Crohn’s disease on calprotectin concentration.41 Upper gut imaging was not performed in 
this study. To be included in the study patients had to have had all macroscopic disease 
removed at the time of surgery. However we cannot exclude that a small number of patients 
may have had upper gut microscopic disease or undetected proximal aphthous ulcers. 
Such minor disease may account for the small number of patients who had an elevated 
fecal calprotectin without endoscopic anastomotic recurrence. Similarly, a small number of 
patients had colonic recurrence without anastomotic recurrence, some of whom had an 
elevated calprotectin concentration.  
 
In conclusion, fecal calprotectin measurement has a potentially valuable role to play in 
monitoring Crohn’s disease patients after intestinal resection. In the setting of detecting 
early recurrence and monitoring the response to treatment it is superior to the serum 
marker of inflammation, CRP, and the clinical index CDAI. Fecal calprotectin testing can be 
performed non-invasively, frequently, cheaply and easily. Calprotectin testing can be 
integrated into the type of post-operative management algorithm demonstrated in the 
POCER study to decrease post-operative recurrence.  
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FIGURE LEGENDS 
 
Figure 1. Consort Diagram: The POCER Study 
 
Figure 2. Fecal calprotectin (FC) in endoscopic remission vs. recurrence at (A) 6 months, 
(B) 18 months; and (C) combined 6 and 18 months. Median FC in remission vs recurrence 
was 72 vs 275 at 6 months (p<0.001), 77 vs 331 at 18 months (p<0.002) and 75 vs 330 
when 6 and 18 month observations were combined (p<0.001). Figure 2D shows all 
matched endoscopy and FC assessments where FC is <300µg/g. The dashed line 
represents the 100µg/g cut-off point. The vast majority of patients with a FC ≤100µg/g in 
this study were in endoscopic remission (Rutgeerts i0 or i1).    
 
Figure 3. Fecal calprotectin (FC) in relation to 6 month endoscopic findings and in 
response to treatment step-up or no change in treatment. Treatment step-up at 6 months 
was associated with a significant reduction in FC at 12 (p=0.005) and 18 months (p=0.004). 
FC trended to increase at both 12 and 18 months in patients in endoscopic remission at 6 
months who did not step up treatment but these changes were not statistically significant.     
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Table 1. Patient demographics 
 
  All (n=135) Endoscopic Validation Cohort (n=99) 
 n = % n = % 
Sex (Male) 59 43.7 46 46.5 
Age (Median) 36 (26-47) 38 (29-47) 
Risk Stratification 
 
   Low Risk 23 17.0 18 18.2 
   High Risk 112 83.0 81 81.8 
Randomisation 
 
   Standard Care 39 28.9 21 21.2 
   Active Care 96 71.1 78 78.8 
Resection Type  
   Ileocaecal 104 77.0 78 78.8 
   Isolated Ileal 9 6.7 6 6.1 
   Subtotal colectomy 6 4.4 6 6.1 
   Ileocaecal and sigmoid 5 3.7 3 3.0 
   Ileocaecal and small bowel 11 8.1 6 6.1 
Disease Location at Surgery 
 
Ileum only (L1) 71 52.6 57 57.6 
Colon only (L2) 10 7.4 7 7.1 
Ileum and colon (L3) 54 40.0 35 35.4 
Upper gastrointestinal disease (L4) 6 4.4 5 5.1 
Disease Phenotype at Surgery 
 
   Inflammatory (B1) 12 8.9 9 9.1 
   Stricturing (B2) 49 36.3 37 37.4 
   Penetrating (B3) 74 54.8 53 53.5 
   Perianal disease (P) 14 10.4 10 10.1 
Smoking at Study Entry 
 
   Never 60 44.4 43 43.4 
   Current 39 28.9 27 27.3 
   Past 36 26.7 29 29.3 
Immediate Post-Operative Drug 
Therapy from Study 
Commencement 
 
   Metronidazole only (Low Risk 
Patients) 23 17.0 18 18.2 
   Thiopurine (High Risk Patients) 76 53.6 55 55.6 
   Adalimumab  (High Risk Thiopurine       
   Intolerant Patients) 36 26.7 26 26.3 
Pre-Operative CDAI, median (IQR) 222 (136.5 - 315.5) 218 (138 - 311) 
Pre-Operative CRP, median (IQR) 10.5 (5 - 48) 9 (5 - 48.5) 
 
Table 2 Analysis cohorts and endoscopic recurrence 
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Analysis 
Cohort 
Patients (n=) Samples (n=) Patients with 
Recurrence at 
6 months 
Patients with 
Recurrence at 
18 months 
Cross Sectional 135 319 31 (36%) 45 (45%) 
Endoscopic 
Validation 
99 137 23 (34%) 24 (35%) 
Longitudinal 80 203 20 (28%) 22 (34%) 
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Table 3. Sensitivity, specificity, positive predictive value (PPV), negative predictive 
value (NPV) and area under the receiver operator characteristic (AUROC) of fecal 
calprotectin (FC) in identifying endoscopic recurrence (Rutgeerts ≥i2) at 6 months, 18 
months, and combined 6 and 18 months. The calculated best cut-off for FC is shown 
first in each table. 
 
 
 FC (µg/g) Sensitivity Specificity PPV (%) 
NPV 
(%) AUROC 
6 months 
n=68 
Calculated best 
cut-off of 135 
0.91 0.62 55 93 
0.799 
50 
 
0.96 0.38 44 94 
100 
 
0.91 0.56 51 93 
150 
 
0.78 0.67 55 86 
200 
 
0.74 0.77 61 85 
1000 
 
0.22 0.93 63 70 
18 months 
n=69 
Calculated best 
cut-off of 
127 
0.88 0.67 58 91 
0.727 
50 
 
0.96 0.36 44 94 
100 
 
0.88 0.58 53 90 
150 
 
0.79 0.69 58 86 
200 
 
0.71 0.71 57 82 
1000 
 
0.17 0.89 44 67 
Combined 6 
and 18 months 
n=139 
Calculated best 
cut-off of 135 
0.87 0.66 56 91 
0.763 
50 
 
0.96 0.38 45 94 
100 
 
0.89 0.58 53 91 
150 
 
0.77 0.68 55 85 
200 
 
0.71 0.74 59 83 
1000 
 
0.19 0.90 50 68 
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Table 4. Correlation between fecal calprotectin (FC) and endoscopic recurrence 
(Rutgeerts score i2 - i4), scored endoscopic severity (score i0 - i4), Simple Endoscopic 
Score for Crohn’s Disease (SES-CD), Crohn’s Disease Endoscopic Index of Severity 
(CDEIS), C-reactive protein (CRP) and Crohn’s Disease Activity Index (CDAI). 
 
 
n=136 
Endoscopic 
Recurrence 
(Rutgeerts 
score i2, i3 or 
i4) 
Scored 
Endoscopic 
Severity (i0-i4) 
SES-CD CDEIS CRP CDAI 
r P R P r P r P r P r P 
FC 0.419 <0.001 0.439 <0.001 0.491 <0.001 0.467 <0.001 0.240 0.121 0.115 1.000 
CDAI -0.153 1.000 
-
0.174 0.978 X X X X 
-
0.167 1.000 X X 
CRP 0.091 1.000 0.166 1.000 X X X X X X X X 
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